Peter S. Reichertz: Lawyer with Sheppard, Mullin, Richter & Hampton LLP

Peter S. Reichertz

Phone202.772.5333

Peer Rating
 5.0/5.0
AV® Preeminent

Client Rating

Featured AV Peer Review Rated Lawyer IconFeatured AV Peer Review Rated Lawyer Icon
Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials Ratings & Reviews
 

Practice Areas

  • Intellectual Property
  • Copyrights
  • False Advertising, Lanham Act and Unfair Competition
  • IP Licensing, Technology and Commercial Transactions
  • Life Sciences and FDA
  • Trademark Applications and Prosecution
  • Trademarks and Trade Dress
  • Advertising
  • Food and Beverage
 
University Brown University, A.B.
 
Law SchoolThe National Law Center, George Washington University, J.D., with honors
 
Admitted1976, District of Columbia; U.S. Supreme Court; U.S. Court of Appeals for the Federal Circuit; U.S. Court of International Trade
 
Memberships 

Memberships

•Member, American Bar Association

•Member, Federal Circuit Bar Association

•Member, International Trademark Association

•Member, Food and Drug Law Institute

•Member, NGLBT Association

 
Biography

Mr. Reichertz is a partner in the Washington D.C. office, and is leader of the firm's Food and Drug Law Group. He also serves as co-leader of the firm's Life Sciences group.

Areas of Practice

Mr. Reichertz concentrates in both food and drug regulatory law and intellectual property law. He counsels companies whose products are regulated by the FDA under the Federal Food Drug and Cosmetic Act. He represents manufacturers and distributors in obtaining approval to market drugs, medical devices, food, dietary supplements and cosmetic products, and counsels on all aspects of marketing of such products, including providing advice on labeling, advertising, manufacturing and distribution issues. He negotiates and prepares clinical trial, distribution, supply, contract manufacturing and quality agreements. He also counsels on related federal and state regulatory statutes.

Mr. Reichertz's practice also includes advising advertising agencies, clinical investigators, research organizations and other non-manufacturers on compliance with the Federal Food Drug and Cosmetic Act. He represents clients in FDA rulemaking proceedings, and in enforcement proceedings brought by the U.S. on behalf of the FDA. Mr. Reichertz also represents clients in advertising disputes related to FDA-regulated products, both at the FDA and in false advertising litigation under Section 43(a) of the Lanham Act and before the National Advertising Division of the Better Business Bureau.

In addition, Mr. Reichertz practices in intellectual property, specifically in trademarks, copyrights, trade secrets and licensing. His trademark expertise includes counseling and advising clients on the selection and adoption of trademarks, as well as the prosecution of trademark applications in the United States Patent and Trademark Office. He also prepares and negotiates trademark licensing agreements.

Honors

•Recommended, Healthcare: Life Sciences, The Legal 500 United States, 2013 and 2014

•Martindale-Hubbell Intellectual Property Washington, D.C. Top Rated Lawyer, 2012

•Washington SmartCEO, Legal Elite, Readers Pick Top Local Attorneys, December 2009 and December 2010

•Which Lawyer?, Life Sciences/Regulatory law, Nationally ranked by Practical Law Company, 2007

 
ISLN902221381
 

Documents by this lawyer on Martindale.com

Subscribe to this feed

New FDA Draft Guidance on REMS and Bioequivalence Studies: Does New Procedure Secure ANDA Applicants The Right to Obtain Samples?
Peter S. Reichertz,Carrie A. Ross, February 5, 2015
Applicants seeking approval of Abbreviated New Drug Applications (ANDAs) in most cases must perform bioequivalence studies comparing their proposed generic product to the innovator drug listed in the Orange Book, called the “Reference Listed Drug” or “RLD”. Issues have...

Update: Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions Before Bringing Suit
Michelle C. Kim,Peter S. Reichertz, February 5, 2015
In our previous blog post of November 11, 2014, we noted that Celltrion had filed a declaratory judgment action against Kennedy Trust for Rheumatology Research for invalidity of certain patents covering methods of treating rheumatoid arthritis. Celltrion Healthcare Co. v. Kennedy Trust for...

FTC Targets Reporting of Licensing of Pharmaceutical Patents With Special Rules for Premerger Notification: What You Need to Know
Peter S. Reichertz, March 25, 2014
On November 15, 2013, the Federal Trade Commission (“FTC”) adopted special rules for determining whether “exclusive” licenses of pharmaceutical patents are required to be reported to the FTC and the Antitrust Division of the Department of Justice under the Hart-Scott-Rodino...


View Ratings & Reviews
Profile Visibility
#401 in weekly profile views out of 57,882 lawyers in Washington, District of Columbia
#17,094 in weekly profile views out of 1,673,393 total lawyers Overall

Office Information

Peter S. Reichertz

Eleventh Floor East, 1300 I Street, NW
WashingtonDC 20005-3314




Loading...
 

Professional Networking for Legal Professionals Only

Quickly and easily expand your professional
network - join the premier global network for legal professionals only. It's powered by the
Martindale-Hubbell database - over 1,000,000 lawyers strong.
Join Now